Anti-cd3 monoclonal antibodies, bispecific antibodies, and uses thereof

By designing anti-CD3 antibodies or antigen-binding fragments that bind weakly in a neutral environment and strongly in an acidic environment, the off-target toxicity and pro-inflammatory cytokine storm problems of CD3 bispecific antibodies have been solved, thereby increasing the local drug concentration in the tumor and enhancing the therapeutic effect.

CN121203020BActive Publication Date: 2026-07-24HEFEI TG IMMUNOPHARMA CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202510733453.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2025-06-03
Publication Date
2026-07-24
Estimated Expiration
2045-06-03

AI Technical Summary

Technical Problem

Existing CD3 bispecific antibodies pose risks of off-target toxicity and pro-inflammatory cytokine storms when treating tumors, affecting their safety and efficacy.

Method used

Design an antibody or antigen-binding fragment that has weak binding to CD3 in a neutral environment and enhanced binding ability in an acidic tumor microenvironment. By modulating affinity distribution of drugs to the tumor site, off-target toxicity can be reduced and therapeutic efficacy improved.

Benefits of technology

While reducing off-target toxicity, it increases the local drug concentration in the tumor, improves the efficacy of treating tumors, autoimmune diseases and inflammatory diseases, reduces the production of pro-inflammatory cytokines, and improves safety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The application provides an anti-CD3 monoclonal antibody, a bispecific antibody and application thereof, and particularly provides an antibody or antigen binding fragment, which comprises CDRs selected from at least one of the following: heavy chain variable region CDRs of SEQ ID NO: 1-3 or a conservatively modified form thereof; light chain variable region CDRs of SEQ ID NO: 4-6 or a conservatively modified form thereof. The antibody or antigen binding fragment has different affinities to CD3 proteins in different pHs, has weak binding capacity in normal pH animal tissues or peripheral blood, has low peripheral drug concentration, reduces the risk of off-target toxicity, has strong affinity to CD3 in tumor tissues or the periphery thereof, is beneficial to the distribution of the antibody to the tumor local part, increases the local drug concentration, and the bispecific antibody prepared from the antibody can promote the combination of T cells and tumor cells, has high safety and specificity, and can effectively treat tumors, autoimmune diseases, inflammatory diseases and / or transplant rejection.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Bispecific antibody targeting PDL1 and CD3 and application thereof

    CN118812720A

  • Bispecific antibodies and uses thereof

    CN119569886A